Compugen Ltd.

CGEN Healthcare Biotechnology

Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024. In the quarter to June 2026, revenue grew 107.0%, EPS grew 12.5% and free cash flow fell 155.4%, each against the same quarter a year earlier.

2.08 0.08 +4.00%
Market cap
$187.6M
P/E
5.5×
Fwd P/E
−7.2×
Dividend yield
—
F-score
7/9
Altman Z
−0.37
Beneish M
−1.59
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
7 5 4 3 — — — — — 2
P/E ratio
4.14 0.00 0.00 0.00 0.00 0.00 — 0.00 — 0.00
P/S ratio
1.96 4.92 11.31 3.96 22.92 48.68 — 6.72 — 364.28
Altman Z-Score
(0.37) (3.87) (2.81) (4.72) 4.19 27.57 — (4.47) — 14.57
P/FCF ratio
1.41 2.16 0.00 0.00 0.00 0.00 — 0.00 — 0.00
Altman Z″-Score (non-manufacturers)
(0.84) (8.87) (7.46) (8.19) (2.53) 1.74 — (16.25) — (1.40)
P/Operating CF
4.52 2.76 (6.84) (2.40) (14.14) (37.64) — (4.68) — (10.13)
Beneish M-Score
(1.59) (5.68) 5.58 (2.68) (1.69) — — — — (5.65)
P/B ratio
1.39 2.49 2.67 0.79 3.39 8.05 — 3.22 — 4.08
Price to Tangible BV
1.39 2.49 2.67 0.79 3.39 8.05 — 3.22 — 4.08
EV/Sales
(0.04) 1.21 8.01 (1.44) 15.46 42.39 — 4.16 — 277.86
EV/EBITDA
0.00 0.00 0.00 0.52 0.00 0.00 — 0.00 — 0.00
EV/Operating CF
(0.03) 0.53 (1.14) 0.24 (3.20) (9.97) — (1.11) — (3.72)
EV/FCF
(0.03) 0.53 (1.13) 0.24 (3.17) (10.00) — (1.10) — (3.32)
Quick Ratio
6.56 5.26 4.36 7.23 7.21 12.27 6.60 4.66 5.03 13.22
Current Ratio
6.56 5.26 4.36 7.23 7.21 12.27 6.60 4.66 5.03 13.22
Net Debt/EBITDA
(4.65) 6.46 3.99 2.40 3.40 4.04 1.57 2.09 0.85 1.98
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.54 0.24 0.31 0.07 0.04 0.02 0.00 0.39 0.00 0.01
Operating CF/Net income
0.90 (3.49) 1.91 1.01 0.67 0.95 1.02 0.59 0.83 0.63
Capex/Depreciation
30.50 0.11 (0.88) (0.99) (0.63) (0.17) 0.23 (0.11) (0.24) (1.75)
ROE
44.84% (23.63%) (26.19%) (36.55%) (30.20%) (37.57%) (72.35%) (67.93%) (79.87%) (41.07%)
ROA
26.03% (12.04%) (17.40%) (29.77%) (25.29%) (30.92%) (51.12%) (49.17%) (67.46%) (36.97%)
ROIC
0.00% 0.00% (55.97%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (1,022.31%)
Return on Tangible Assets
28.02% (16.42%) (20.95%) (44.49%) (31.73%) (24.69%) (67.47%) (56.55%) (125.09%) (49.30%)
Average Days of Receivables
11.95 35.92 693.03 117.63 332.15 850.09 0.00 18.52 0.00 591.07
Research and Development Expense of Revenue
31.28% 89.04% 103.03% 408.64% 478.23% 1,138.00% 0.00% 170.33% 0.00% 3,447.89%
Selling, General and Administrative Expense of Revenue
12.96% 35.94% 29.81% 150.01% 195.00% 533.80% 0.00% 54.35% 0.00% 1,197.05%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
2.59% 10.85% 10.61% 57.71% 71.27% 138.60% 0.00% 12.17% 0.00% 433.15%
Graham Net Nets
0.66 0.34 0.34 1.13 0.27 0.11 — 0.26 — 0.21
Graham Number
3.03 0.00 0.00 0.00 0.00 0.00 — 0.00 — 0.00
Earnings Yield
24.18% (10.18%) (11.00%) (56.34%) (9.30%) (3.06%) — (18.34%) — (12.16%)
Free Cash Flow Yield
71.14% 46.22% (62.89%) (150.38%) (21.27%) (8.71%) — (56.50%) — (22.97%)
Revenue per Share
0.78 0.31 0.38 0.09 0.07 0.03 0.00 0.32 0.00 0.01
Operating CF per Share
0.34 0.55 (0.41) (0.39) (0.27) (0.36) (0.44) (0.24) (0.60) (0.39)
Capex per Share
0.00 0.00 0.00 (0.01) 0.00 0.00 0.00 0.00 (0.01) (0.05)
Free Cash Flow per Share
0.34 0.55 (0.41) (0.40) (0.27) (0.36) (0.43) (0.24) (0.61) (0.44)
Cash per Share
1.56 1.15 0.58 0.97 1.40 1.56 0.69 0.83 0.59 1.21
Shareholders Equity per Share
1.10 0.61 0.75 0.90 1.27 1.51 0.60 0.67 0.57 1.25
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
1.10 0.61 0.75 0.90 1.27 1.51 0.60 0.67 0.57 1.25
Free Cash Flow
31.33 49.49 (36.06) (34.59) (23.04) (28.44) (27.66) (13.45) (31.04) (22.42)
Working Capital
125.45 85.84 88.31 74.21 106.13 118.57 38.18 36.59 24.99 57.94
Capital Expenditures
(0.30) (0.12) (0.17) (0.47) (0.29) (0.12) 0.23 (0.16) (0.38) (2.60)
Net Current Asset Value
94.18 45.92 58.80 69.63 97.75 110.56 29.56 30.64 21.73 55.06
EV/EBIT
0.00 0.00 0.00 0.63 0.00 0.00 — 0.00 — 0.00
Capex to Sales
0.00 0.00 0.01 0.06 0.05 0.06 0.00 0.01 0.00 3.65
Price to Operating Income
4.56 0.00 0.00 0.00 0.00 0.00 — 0.00 — 0.00
Other line items
Depreciation/Fixed assets
(0.01) (1.28) 0.16 0.31 0.28 0.42 0.42 0.41 0.34 0.25
Cash ROIC
12.61% 31.29% (30.92%) (21.43%) (10.26%) (11.65%) (33.65%) (16.22%) (51.97%) (17.93%)
Accounts Receivable Turnover
28.40 0.84 1.01 1.90 1.19 0.69 0.00 21.65 0.00 0.14
Accounts Payable Turnover
4.41 2.97 0.76 0.31 0.23 0.05 0.49 0.32 0.68 0.14
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Days of Payables
92.84 84.60 637.84 663.74 2,480.39 8,595.75 401.54 1,039.93 789.34 2,085.25
Days of Inventory on Hand
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Receivables
2.56 33.14 32.97 3.94 5.06 2.89 1.01 0.82 0.95 5.15
Average Payables
2.10 2.67 2.64 3.20 3.02 1.25 2.02 3.20 2.36 1.64
Average Assets
135.78 118.16 107.76 113.17 135.24 96.04 53.47 45.96 54.94 85.22
Average Common Equity
78.82 60.24 71.62 92.19 113.24 79.05 37.78 33.27 46.41 76.71

Fold the line items

Columns are period end dates